» Articles » PMID: 39596986

Perindopril Ameliorates Sodium Valproate-Induced Rat Model of Autism: Involvement of Sirtuin-1, JAK2/STAT3 Axis, PI3K/Akt/GSK-3β Pathway, and PPAR-Gamma Signaling

Overview
Publisher MDPI
Specialty General Medicine
Date 2024 Nov 27
PMID 39596986
Authors
Affiliations
Soon will be listed here.
Abstract

Autism is a developmental disability characterized by impairment of motor functions and social communication together with the development of repetitive or stereotyped behaviors. Neither the exact etiology or the curative treatment of autism are yet completely explored. The goals of this study were to evaluate the possible effects of perindopril on a rat model of autism and to elucidate the possible molecular mechanisms that may contribute to these effects. In a rat model of sodium valproate (VPA)-induced autism, the effect of postnatal administration of different doses of perindopril on growth and motor development, social and repetitive behaviors, sirtuin-1, oxidative stress and inflammatory markers, PI3K/Akt/GSK-3β pathway, JAK2/STAT3 axis, and PPAR-gamma signaling in the hippocampal tissues were investigated. The histopathological and electron microscopic changes elicited by administration of the different treatments were also investigated. : Perindopril dose-dependently combatted the effects of prenatal exposure to VPA on growth and maturation, motor development, and social and repetitive behaviors. In addition, the different doses of perindopril ameliorated the effects of prenatal exposure to VPA on sirtuin-1, oxidative stress and inflammatory markers, PI3K/Akt/GSK-3β pathway, JAK2/STAT3 axis, and PPAR-gamma signaling. These effects had a mitigating impact on VPA-induced histopathological and electron microscopic changes in the hippocampal tissues. : Perindopril may emerge as a promising agent for amelioration of the pathologic changes of autism spectrum disorders.

Citing Articles

BDNF and GSK-3beta expression changes underlie the beneficial effects of crocin on behavioral alterations in a rat model of autism induced by prenatal valproic acid administration.

Hosseini S, Ghadimi M, Reyhani N, Khazaei S, Rahmatkhah-Yazdi M, Soleimani-Farsani R Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39777538 DOI: 10.1007/s00210-024-03777-2.

References
1.
Jiang S, Xiao L, Sun Y, He M, Gao C, Zhu C . The GABAB receptor agonist STX209 reverses the autism‑like behaviour in an animal model of autism induced by prenatal exposure to valproic acid. Mol Med Rep. 2022; 25(5). PMC: 8941376. DOI: 10.3892/mmr.2022.12670. View

2.
Jin Y, Choi J, Lee S, Kim J, Hong Y . Pathogenetical and Neurophysiological Features of Patients with Autism Spectrum Disorder: Phenomena and Diagnoses. J Clin Med. 2019; 8(10). PMC: 6832208. DOI: 10.3390/jcm8101588. View

3.
Malaguarnera M, Khan H, Cauli O . Resveratrol in Autism Spectrum Disorders: Behavioral and Molecular Effects. Antioxidants (Basel). 2020; 9(3). PMC: 7139867. DOI: 10.3390/antiox9030188. View

4.
Salminen A, Kaarniranta K, Kauppinen A . Crosstalk between Oxidative Stress and SIRT1: Impact on the Aging Process. Int J Mol Sci. 2013; 14(2):3834-59. PMC: 3588074. DOI: 10.3390/ijms14023834. View

5.
Chaloob M, Ali H, Qasim B, Mohammed A . Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study. Oman Med J. 2012; 27(5):368-74. PMC: 3472582. DOI: 10.5001/omj.2012.93. View